Glycine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Glycine
- Pharmacist Assessment Report
- Glycine: From Allergic Rhinitis and Related Upper Respiratory Conditions to Nasal Cavity Disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Glycine: From Allergic Rhinitis and Related Upper Respiratory Conditions to Nasal Cavity Disease
One-Sentence Summary
Glycine is an amino acid. The knowledge base used for this report lists its original indications as upper respiratory conditions such as allergic rhinitis, rhinitis, pharyngitis, common cold and nasopharyngitis. The TxGNN model predicts it may be effective for nasal cavity disease, but the evidence is very thin: 1 clinical trial (judged incidental) and 2 publications (neither tests glycine as a treatment). This is essentially a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, pharyngitis, common cold, rhinitis, nasopharyngitis (from the knowledge base; the India licence records contain no approved indication text) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9985 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data |
| Number of Listed Products | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, glycine is a simple amino acid already marketed in India as an oral tablet and as an irrigation solution. Its listed original indications are upper respiratory conditions, and mechanistically it may be applicable to nasal cavity disease, but the data compiled for this report do not support a direct mechanistic link.
“Nasal cavity disease” is a broad category that overlaps heavily with the existing indications (allergic rhinitis, rhinitis, nasopharyngitis). The high score is therefore likely the model extrapolating within the same disease family rather than identifying a genuinely new use. The predicted indication is not a clear repurposing opportunity.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01806675 | Phase 1/2 | Completed | 25 | PET imaging study of a new radiotracer (18F-FPPRGD2) for angiogenesis in glioblastoma, gynaecological cancers and renal cell carcinoma. It does not evaluate glycine as a treatment and does not involve nasal disease. The match appears incidental. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29607903 | 2018 | Preclinical research | Chemical & Pharmaceutical Bulletin | Oligoarginine-linked polymers as a mucosal adjuvant for nasal influenza vaccination in mice. Glycine is not tested as a therapy. |
| 7771054 | 1995 | Basic research (veterinary) | Veterinary Pathology | Lectin histochemistry of normal and herpesvirus-infected bovine nasal mucosa. Glycine is not tested as a therapy. |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 50734 | Country Life Glycine 500mg Tablet | Jar of 100 tablets (oral) | Not specified |
| Registration No. 95288 | Glycine Irrigation 1.5% Infusion | Bottle of 3000 ml infusion | Not specified |
Safety Considerations
The knowledge base lists the following diseases as contraindications for glycine. These come from knowledge-graph relationships, not from package insert text:
- Kidney and urinary conditions: kidney disease, chronic kidney disease, chronic renal failure, end stage renal failure, nephrolithiasis, nephrocalcinosis, acute urate nephropathy, pyoureter
- Calcium, phosphorus and parathyroid disorders: hypercalcemia, humoral hypercalcemia of malignancy, hyperparathyroidism, osteitis fibrosa, hyperphosphatemia, phosphorus metabolism disease, hypervitaminosis, sarcoidosis, lytic metastatic bone lesion
- Cardiovascular conditions: heart disease, cardiovascular disease, arteriosclerosis obliterans, digitalis poisoning, ventricular fibrillation
- Metabolic and other: phenylketonuria, disorders of phenylalanine metabolism, constipation disorder
No drug interaction records were found. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. The single trial found is an unrelated imaging study, the two publications do not test glycine, and the predicted indication largely overlaps with existing upper respiratory uses.
To proceed, the following is needed:
- Mechanism of action data for glycine, to assess a plausible link to nasal cavity disease
- Approved indication text and package insert warnings and contraindications for the India-marketed products
- Clinical or preclinical studies that actually test glycine in nasal or laryngopharyngeal conditions
- Clarification of whether nasal cavity disease is truly distinct from the existing labelled uses
- Route compatibility assessment (oral and irrigation forms are available; the route needed for the new indication is not yet defined)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.